丰原药业股价微涨0.99% 控股股东协议转让5.1%股份

Core Viewpoint - Fengyuan Pharmaceutical's stock price has increased by 0.99% to 7.14 yuan, with a total market capitalization of 3.318 billion yuan and a price-to-earnings ratio of 21.82 times [1] Group 1: Financial Performance - The company reported that its revenue contributions from drug manufacturing and retail distribution are 46.65% and 49.75% respectively for the year 2024 [1] - The total trading volume for the day was 117 million yuan, with the stock reaching a high of 7.16 yuan and a low of 7.02 yuan during trading [1] Group 2: Share Transfer Announcement - On August 11, the company announced that its controlling shareholder, Fengyuan Group, along with its concerted parties, plans to transfer 23.6986 million shares, representing 5.1% of the total share capital, to Hainan Guihe Dayi Investment Partnership through a private agreement [1] - The transfer price is set at 6.72 yuan per share, totaling 159 million yuan, with the acquiring party expressing confidence in the company's future development [1]